This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn  

Media enquiries: comms@oxfordsp.com 

Scancell gets FDA approval to move into final-stage trial for new melanoma treatment

Scancell gets FDA approval to move into final-stage trial for new melanoma treatment

26 Jan 2026

Scancell has received approval from the US Food and Drug Administration (FDA) to begin a large, late-stage clinical trial of its skin cancer treatment, iSCIB1+  Immunobody®. The Phase 3 trial, which is planned to start this year, will test whether iSCIB1+ can help people with advanced melanoma live longer without their cancer getting worse. Results from Scancell’s earlier Phase 2 study are very encouraging. Patients who received iSCIB1+... Read more

Oxford Nanopore receives regulatory approval for its first diagnostic device in the UK and Europe

Oxford Nanopore receives regulatory approval for its first diagnostic device in the UK and Europe

13 Jan 2026

Oxford Nanopore Technologies has announced that the GridION™ Dx is now both CE and UKCA marked, making it the company’s first In Vitro Diagnostic (IVD) device registered in the UK and Europe. The CE and UKCA certification confirms that GridION Dx meets stringent international standards for quality, safety, and performance, positioning Oxford Nanopore for future adoption in regulated clinical markets and reflecting its long-term commitment to... Read more

Moa and Certis Belchim sign strategic collaboration deal

Moa and Certis Belchim sign strategic collaboration deal

08 Jan 2026

  Netherlands-based company becomes Moa's third major commercial partner in 18 months. Moa Technology and Certis Belchim have announced a new strategic collaboration, marking a significant step forward in the development of next-generation herbicides for global agriculture. This partnership brings together Moa Technology’s breakthrough discovery platforms, which have identified over 80 new herbicidal modes of action in the past three... Read more

Dark Blue Therapeutics acquired by Amgen to bolster oncology pipeline

Dark Blue Therapeutics acquired by Amgen to bolster oncology pipeline

06 Jan 2026

Dark BlueTherapeutics, located at The Oxford Science Park, has been acquired by global biopharmaceutical company Amgen, in a transaction valued at up to $840 million.   Based on unique academic insights from the University of Oxford, the team at Dark Blue Therapeutics are developing a small molecule that targets and degrades two proteins that drive specific types of acute myeloid leukemia, a fast-growing blood cancer. Dark Blue says its... Read more